高级搜索

替吉奥胶囊联合奥沙利铂方案加贝伐单抗治疗晚期结直肠癌的临床观察

张凯, 刘培培, 张伟杰, 王留兴

张凯, 刘培培, 张伟杰, 王留兴. 替吉奥胶囊联合奥沙利铂方案加贝伐单抗治疗晚期结直肠癌的临床观察[J]. 肿瘤防治研究, 2014, 41(09): 1036-1039. DOI: 10.3971/j.issn.1000-8578.2014.09.017
引用本文: 张凯, 刘培培, 张伟杰, 王留兴. 替吉奥胶囊联合奥沙利铂方案加贝伐单抗治疗晚期结直肠癌的临床观察[J]. 肿瘤防治研究, 2014, 41(09): 1036-1039. DOI: 10.3971/j.issn.1000-8578.2014.09.017
shu
ZHANG Kai, LIU Peipei, ZHANG Weijie, WANG Liuxing. Oxaliplatin Combined with S-1 plus Bevacizumab Regimen in Treatment of Advanced Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(09): 1036-1039. DOI: 10.3971/j.issn.1000-8578.2014.09.017
Citation: ZHANG Kai, LIU Peipei, ZHANG Weijie, WANG Liuxing. Oxaliplatin Combined with S-1 plus Bevacizumab Regimen in Treatment of Advanced Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(09): 1036-1039. DOI: 10.3971/j.issn.1000-8578.2014.09.017
shu

替吉奥胶囊联合奥沙利铂方案加贝伐单抗治疗晚期结直肠癌的临床观察

  • 450052 郑州，郑州大学第一附属医院肿瘤科一病区

详细信息
    作者简介:

    张凯（1986-），男，硕士在读，主要从事恶性肿瘤的综合治疗研究

    通讯作者:

    王留兴，E-mail：wlx2246@126.com.cn

  • 中图分类号: R735.3

Oxaliplatin Combined with S-1 plus Bevacizumab Regimen in Treatment of Advanced Colorectal Cancer

  • Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

HTML全文

    摘要
  • 摘要: 目的 观察替吉奥胶囊联合奥沙利铂方案加贝伐单抗治疗晚期结直肠癌的临床疗效及不良反应，评价其有效性和安全性。 方法 回顾性分析2010年6月-2012年6月收治的经病理学确诊的47例晚期结直肠癌病例，其中22例采用替吉奥胶囊联合奥沙利铂方案加贝伐单抗治疗(研究组)，25例采用单纯替吉奥胶囊联合奥沙利铂方案治疗(对照组)，观察其疗效和不良反应，并进行随访。结果 47例患者均可评价疗效和不良反应，研究组和对照组的客观有效率分别为63.6%和36.0%；疾病控制率分别为86.4%和68.0%；中位无疾病进展期分别为7.3月和4.8月；中位生存期分别为15.0月和12.6月，差异均具有统计学意义(P<0.05)；研究组较对照组增加的不良反应主要有高血压，出血等, 发生率分别为9.1% 、4.5%，均为Ⅰ级~Ⅱ级，经药物治疗后均可控制，不影响化疗的连续性。 结论 替吉奥胶囊联合奥沙利铂方案加贝伐单抗治疗晚期结直肠癌能够提高疗效，延长生存时间，且患者耐受性较好，具有较好的临床应用前景。

     

    Abstract: Objective To observe the clinical efficacy and adverse reactions of oxaliplatin combined with S-1 plus bevacizumab regimen in the treatment of advanced colorectal cancer. Methods We made a retrospective analysis of hospitalized 47 cases of advanced colorectal cancer diagnosed pathologically from Jun 2010 to Jun 2012, and divided them into two groups, the study group received oxaliplatin combined with S-1 plus bevacizumab regimen (n=22) and the control group received oxaliplatin combined with S-1 regimen only (n=25). The efficacy and side effects of two groups were observed and compared. Results The objective response rates were 63.6% in the study group and 36.0% in control group, and the disease control rates were 86.4% and 68.0% (P>0.05), the median progression-free survival time were 7.3 and 4.8 months (P<0.05), and the median overall survival time were 15.0 and 12.6 months (P<0.05). The increased adverse reactions in the study group included hypertension and bleeding, with the incidence rates of 9.1% and 4.5%, respectively, however, as all were of Grade I and Ⅱ, they could be controlled after drug treatment and did not affect the continuity of chemotherapy. Conclusion Oxaliplatin combined with S-1 plus bevacizumab regimen could improve the clinical efficacy of advanced colorectal cancer, prolong the survival time and has good tolerance in the patients. Therefore, it has promising prospects in clinical application.

     

    • HTML全文
    • 参考文献(13)
  • [1] Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4): 225-49.
    [2] Salgaller ML.Technology evaluation:bevacizumab,Genentech/ Roche[J].Curr Opin Mol Ther,2003,5(6):657-67.
    [3] Chen HX, Mooney M, Boron M, et al.Phase Ⅱ multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center trial TRC-0301[J]. J Clin Oncol,2006,24(21):3354-60.
    [4] Ni TG,Guan QL,Wang N,et al.Bevacizumab plus chemotherapy as first-line therapy for metastatic colorectal cancer: a systematic review of the efficacy and safety[J].Zhong Liu,2010,30(3):232-8.[倪田根,关泉林,王娜,等. 贝伐单抗联合 化疗一线治疗转移性结直肠癌有效性和安全的系统评价[J].肿 瘤,2010,30(3):232-8.]
    [5] Daisuke T,Yasuhide Y,Hiroshi M,et al.A randomized phase Ⅲ trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-Fu/ l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study[J]. J Clin Oncol, 20 13,31(6):3519-24.
    [6] Giacchetti S, Perpoint B, Zidani R,et al.Phase Ⅲ multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer[J]. J Clin Oncol,2000,18(1): 136-47.
    [7] Douillard JY,Cunningham D,Roth AD,et al.Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial[J]. Lancet, 2000, 355 (9209): 1041-7.
    [8] Chollet P,Schoffski P,Weigang-kohler K,et al. Phase Ⅱ trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)[J]. Eur J Cancer, 2003, 39(9): 1264-70.
    [9] Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis[J]. J Mol Med, 2003,81(1): 20-31.
    [10] Wang Y,Fei D,Vanderlaan M,et al.Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro[J].Angio genesis,2004,7(4):335-45.
    [11] Hurwitz H, Fehrenbacher L, Novotny W, et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med,2004,350(23):2335-42.
    [12] Giantonio BJ,Catalano PJ,Meropol NJ,et al.Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 [J]. J Clin Oncol,2007,25(12):1539-44.
    [13] Lv Q, Feng GG. Bevacizumab combined with CapOx in treatment of advanced colorectal cancer[J].Xian Dai Zhong Xi Yi Jie He Za Zhi,2011,20(18):2213-5,2218.[吕强,冯国光.贝伐单抗联合 CapeOx化疗治疗晚期结直肠癌的临床研究[J].现代中西医结 合杂志,2011,20(18):2213-5, 2218.]
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  2040
  • HTML全文浏览量:  315
  • PDF下载量:  639
  • 被引次数: 0
出版历程
  • 刊出日期:  2014-09-24

目录

摘要
HTML全文
    参考文献(13)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：12495954 今日访问：12725

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭